Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 cells in relapsed/refractory B-cell ALL
NCT03391739Phase 3Unknown
- Sponsor
- Fujian Medical University
- Start
- Jan 2016
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 3, open-label trial of CART-19 cells in acute lymphoblastic leukemia (ALL), sponsored by Fujian Medical University. Primary endpoint: Leukemia Free Survival at 1 year. Status: unknown.
02
Drugs
CART-19 cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03391739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391739.